Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

thehindu.com -  Bindu Shajan Perappadan - Advocacy group questions Medanta MD Naresh Trehan's inclusion in panel on pharma marketing practices
Advocacy group questions Medanta MD Naresh Trehan's inclusion in panel on pharma marketing practices
The Hindu –

The Working Group on Access to Medicines and Treatments has raised concerns over including Dr. Naresh Trehan, chairman and managing director of Medanta, in a committee constituted on the Supreme Court's directions to examine the regulatory…

thehindubusinessline.com - Torrent Pharma eyes semaglutide launch in Brazil in 6-9 months
Torrent Pharma eyes semaglutide launch in Brazil in 6-9 months
BusinessLine –

Torrent Pharmaceuticals plans to launch semaglutide in Brazil over the next six to nine months, as the drugmaker seeks to expand its presence in a market where revenues grew 38 per cent in the September quarter, Managing Director Aman Mehta said.

fool.com - Reuben Gregg Brewer - Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead
Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead
The Motley Fool –

Biotech companies are high-risk, high-reward investments. Usually, a biotech has just one drug in development, and if it gets that drug to market, you win. If the drug doesn't work out, you lose. You don't have to make binary bets like that if you…

marketbeat.com - Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Price Target of $6.67 According to Analysts
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Price Target of $6.67 According to Analysts
MarketBeat –

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) has received an average recommendation of 'Moderate Buy' from the six research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst…

businessinsider.com - Truman Dickerson - After a long, strange trip, this CEO is close to taking a psilocybin pill to market
After a long, strange trip, this CEO is close to taking a psilocybin pill to market
Business Insider –

In 2022, Kabir Nath had a cushy executive job at a pharmaceutical firm that developed anti-psychotic medication. Then he got a call from a scrappy upstart with a patent on a synthetic version of psilocybin — the active ingredient in magic…

swissinfo.ch - swissinfo.ch - Data security breaches rise in 2026
Data security breaches rise in 2026
www.swissinfo.ch –

There were 343 such incidents throughout 2025. However, the actual number of incidents is likely to be significantly higher, as there are a large number of unreported cases, he said in an interview with the Swiss German weekly Sonntagsblick.

rediff.com - Text Feed - Bristlecone's 24% Growth Fuels Billion-Dollar Valuation Ambition
Bristlecone's 24% Growth Fuels Billion-Dollar Valuation Ambition
Rediff.com –

Discover how Mahindra Group's Bristlecone is leveraging a 24 per cent year-on-year growth and strategic AI investments to pursue a billion-dollar valuation in the competitive supply chain services market. Bristlecone, a Mahindra Group firm…

thehindu.com -  The Hindu Bureau - KSSP supports distribution of generic drugs for SMA patients in Keralam
KSSP supports distribution of generic drugs for SMA patients in Keralam
The Hindu –

Updated - October 25, 2026 01:27 pm IST - Kozhikode Subscribe to The Hindu @ Just ₹1* Subscribe to The Hindu @ Just $4.99 *Offer only for new subscribers The Kerala Sastra Sahitya Parishad (KSSP) has supported the Kerala Health Department's…

247wallst.com - Rich Duprey - Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29
Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29
24/7 Wall St –

Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings? Merck stock sits near analyst targets…

247wallst.com - Rich Duprey - Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
24/7 Wall St –

Dow Jones52,284.00−1.20% Russell 20002,778.71−0.12% Dow Jones52,284.00−1.20% Russell 20002,778.71−0.12% Dow Jones52,284.00−1.20% Russell 20002,778.71−0.12% Dow Jones52,284.00−1.20% Russell…

marketbeat.com - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Now Rated 'Moderate Buy' by Sell-Side Brokerages
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Now Rated 'Moderate Buy' by Sell-Side Brokerages
MarketBeat –

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) have received an average recommendation of 'Moderate Buy' from the fourteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has…

lionessofjudah.substack.com - Lioness of Judah Ministry - SHOCKING: Sasha Latypova Exposes the Government-Led DEATH CULT Behind COVID
SHOCKING: Sasha Latypova Exposes the Government-Led DEATH CULT Behind COVID
Exposing The Darkness –

Exposing The Darkness is a reader-supported publication. To support my work, please consider becoming a paid subscriber. One-time or recurring donations can be made through Ko-Fi: ⚡ What aren't they telling you? Please Join Exposing the…

marketbeat.com - 106,238 Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Sterling Capital Management LLC
106,238 Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Sterling Capital Management LLC
MarketBeat –

Sterling Capital Management LLC decreased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 37.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange…

marketbeat.com - argenex (NASDAQ:ARGX) Cut to 'Hold' at Wall Street Zen
argenex (NASDAQ:ARGX) Cut to 'Hold' at Wall Street Zen
MarketBeat –

argenex (NASDAQ:ARGX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a 'buy' rating to a 'hold' rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports. 2 Ways to Play the Big…

bonnerprivateresearch.com - Bill Bonner - BPR: Follow the Money
BPR: Follow the Money
Bonner Private Research –

That's what ‘ Deep Throat ' tells Woodward and Bernstein in the 1976 movie ‘ All the President's Men.' The line was made up by a screen writer. But Deep Throat was real. It was Mark Felt, who'd been passed over for the Director's job…

Receive a Daily briefing on Pharma Industry News

Get Started